4
Apr 2023
FF/VI is an inhaled therapy for the treatment of asthma, with a prolonged duration of antiinflammatory and bronchodilatory action.1 This study investigated the global metabolomic and lipidomic profile following treatment with FF/ VI or placebo and assessed whether changes correlated with exhaled nitric oxide levels as a measure of airway inflammation.1 Despite the prolonged airway antiinflammatory action, this study detected only a subtle systemic metabolomic and lipidomic changes with FF/VI treatment.1
To report an Adverse Event, please contact the toll free line 0800 CALL GSK (0800 2255 475) or send an email